These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24522814)

  • 1. Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.
    Mussi SV; Sawant R; Perche F; Oliveira MC; Azevedo RB; Ferreira LA; Torchilin VP
    Pharm Res; 2014 Aug; 31(8):1882-92. PubMed ID: 24522814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models.
    Oliveira MS; Aryasomayajula B; Pattni B; Mussi SV; Ferreira LAM; Torchilin VP
    Int J Pharm; 2016 Oct; 512(1):292-300. PubMed ID: 27568499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
    Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
    AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
    Li X; Jia X; Niu H
    Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
    Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
    Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells.
    Zhang XG; Miao J; Dai YQ; Du YZ; Yuan H; Hu FQ
    Int J Pharm; 2008 Sep; 361(1-2):239-44. PubMed ID: 18586075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles.
    Mussi SV; Silva RC; Oliveira MC; Lucci CM; Azevedo RB; Ferreira LA
    Eur J Pharm Sci; 2013 Jan; 48(1-2):282-90. PubMed ID: 23178339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride.
    Wang J; Wu L; Kou L; Xu M; Sun J; Wang Y; Fu Q; Zhang P; He Z
    Int J Pharm; 2016 Nov; 513(1-2):218-226. PubMed ID: 27628785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model.
    Fernandes RS; Silva JO; Mussi SV; Lopes SCA; Leite EA; Cassali GD; Cardoso VN; Townsend DM; Colletti PM; Ferreira LAM; Rubello D; de Barros ALB
    Mol Imaging Biol; 2018 Jun; 20(3):437-447. PubMed ID: 29043471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-based nanocarriers co-loaded with artemether and triglycerides of docosahexaenoic acid: Effects on human breast cancer cells.
    Lanna EG; Siqueira RP; Machado MGC; de Souza A; Trindade IC; Branquinho RT; Mosqueira VCF
    Biomed Pharmacother; 2021 Feb; 134():111114. PubMed ID: 33352447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
    Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
    Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
    Shen Q; Qiu L
    J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TPGS-functionalized and ortho ester-crosslinked dextran nanogels for enhanced cytotoxicity on multidrug resistant tumor cells.
    Sun M; Wang X; Cheng X; He L; Yan G; Tang R
    Carbohydr Polym; 2018 Oct; 198():142-154. PubMed ID: 30092984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
    Siddiqui A; Patwardhan GA; Liu YY; Nazzal S
    Int J Pharm; 2010 Nov; 400(1-2):251-9. PubMed ID: 20816930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.
    Hao T; Chen D; Liu K; Qi Y; Tian Y; Sun P; Liu Y; Li Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):18064-75. PubMed ID: 26214761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin and doxorubicin co-encapsulated biotin receptor-targeting nanoparticles for minimizing drug resistance in breast cancer.
    Lv L; Liu C; Chen C; Yu X; Chen G; Shi Y; Qin F; Ou J; Qiu K; Li G
    Oncotarget; 2016 May; 7(22):32184-99. PubMed ID: 27058756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
    Liu Q; Li J; Pu G; Zhang F; Liu H; Zhang Y
    Drug Deliv; 2016 May; 23(4):1364-8. PubMed ID: 25874959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug.
    Chinsriwongkul A; Chareanputtakhun P; Ngawhirunpat T; Rojanarata T; Sila-on W; Ruktanonchai U; Opanasopit P
    AAPS PharmSciTech; 2012 Mar; 13(1):150-8. PubMed ID: 22167418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
    Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.